{ "ok": true, "cik": "873303", "ticker": "SRPT", "name": "SAREPTA THERAPEUTICS, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-23", "items": [ "1.01 Entry into a Material Definitive Agreement" ], "url": "https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/0001193125-26-399416-index.htm" }, { "form": "8-K", "filed": "2026-08-05", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/0001193125-26-335056-index.htm" }, { "form": "10-Q", "filed": "2026-08-05", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/873303/000119312526335003/0001193125-26-335003-index.htm" }, { "form": "8-K", "filed": "2026-07-27", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm" }, { "form": "8-K", "filed": "2026-06-04", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "5.07 Submission of Matters to a Vote of Security Holders", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm" }, { "form": "8-K", "filed": "2026-05-06", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/0001193125-26-208966-index.htm" } ], "events12m": 12, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000873303.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=873303" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up SAREPTA THERAPEUTICS, INC. ($SRPT). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-23. 12 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 2198237000, "revenueGrowth1y": 0.15576302367165984, "revenueGrowthPerYear": 0.3303068541248986, "yearsOfData": 5, "operatingMargin": -0.3183373767250756, "operatingMarginPrior": 0.11466004619399058, "netMargin": -0.3245373451543214, "operatingCashFlow": -205479000, "capitalSpending": 101972000, "freeCashFlow": -307451000, "researchAndDevelopment": 1522066000, "researchShareOfRevenue": 0.6924030484429113, "cash": 801282000, "longTermDebt": 828974000, "longTermDebtChange": -0.2709906747197315, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 701887000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 933013000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 1243336000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 1901979000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 2198237000 } ], "totalEquity": 1140622000, "totalAssets": 3349703000, "equityRatio": 0.34051436799023677, "returnOnEquity": -0.6254569875033096, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -7.13, "sharesOutstanding": 100120000, "bookValuePerShare": 11.392548941270475, "revenuePerShare": 21.956022772672792, "range80": { "low": 2301196988.9674497, "high": 3098411326.1012964, "baseline": 2732857281.0845094, "n": 4599, "band": "b1", "bandLabel": "$1B–10B", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.11445257800484324, "classVolatility": 0.07701947805587882, "volatility": 0.09754843056644921 }, "ifPaceHeld": { "low": 2301196988.9674497, "high": 3098411326.1012964 } }, "edgarette": "🔖 Exposure: revenue $2.2B (FY2025), total debt $829.0M. Experience: revenue up 15.6% on the year, up 33.0% a year over 4 years; operating margin -31.8%, down from 11.5%. Soundness: equity 34.1% of assets, return on equity -62.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.3B and $3.1B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $2.1B to $3.5B. A range, not a forecast. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -31.8% against a -3.8% median; growth 15.6% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Sarepta Therapeutics (SRPT) grew revenue 15.6% in FY2025 to $2.2 billion, operating margin -31.8% against a -3.8% median for pharmaceutical preparations, equity 34.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
SAREPTA THERAPEUTICS, INC. against its own record and its peers
Operating marginPeer median -3.8%-31.8%Revenue, on the yearPeer median 13.7%15.6%Equity of assetsPeer median 40.3%34.1%Return on equityPeer median -1.1%-62.5%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 8, "hits": 4, "rate": 0.5, "method": "v4", "byYear": { "2018": [ 0, 1 ], "2019": [ 0, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 1, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-24T14:19:38.435Z", "hash": "ada272f1adf1a6af", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Sarepta Therapeutics (SRPT) grew revenue 15.6% in FY2025 to $2.2 billion, operating margin -31.8% against a -3.8% median for pharmaceutical preparations, equity 34.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 2198237000, "totalDebt": 828974000, "cash": 801282000 }, "experience": { "revenueGrowth1y": 0.15576302367165984, "revenueGrowthPerYear": 0.3303068541248986, "operatingMargin": -0.3183373767250756, "operatingMarginPrior": 0.11466004619399058, "netMargin": -0.3245373451543214, "freeCashFlow": -307451000 }, "soundness": { "equityRatio": 0.34051436799023677, "returnOnEquity": -0.6254569875033096, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 2301196988.9674497, "high": 3098411326.1012964, "baseline": 2732857281.0845094, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 4599, "sizeBand": "$1B–10B", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.11445257800484324, "classVolatility": 0.07701947805587882, "pricedVolatility": 0.09754843056644921, "k": 3 }, "stress": { "low": 2064306902.8465164, "high": 3454332692.4399157, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 8, "hits": 4, "rate": 0.5, "method": "v4", "byYear": { "2018": [ 0, 1 ], "2019": [ 0, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 1, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-24T14:19:38.435Z", "hash": "ada272f1adf1a6af", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000873303.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=873303" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }